CGON CG Oncology, Inc. Insider Trading

Director Mulay James sold entire 15,600 share position in CGON at $73.01, liquidating holding to zero

Mulay James, a Director at CG Oncology, liquidated his entire stake of 15,600 shares (15.6K shares) in a single transaction at $73.01 on 2026-04-17, yielding $1,138,956.00 ($1.1M) and reducing his holdings to zero. This complete exit represents a -100.0% reduction of his pre-transaction position. The sale occurred near the company's 52-week high of $73.43, within 0.6% of the annual peak. Notably, CGON is a biotech/oncology company with only $1,666,000.00 ($1.7M) in latest quarterly revenue but a $5,944,238,080.00 ($5.9B) market cap—a highly speculative valuation gap typical of clinical-stage biotech firms. The company posted a net loss of $-43,808,000.00 ($-43.8M) over its most recent full fiscal year and remains unprofitable, which is standard for preclinical assets. The complete sale of a director's entire position near the 52-week high warrants attention given the fundamental cash burn rate and the stage of the company's pipeline.

Director Liu Brian Guan-Chyun acquires 1,515,151 shares of CGON for $49,999,983.00 on open market

Director Liu Brian Guan-Chyun purchased 1,515,151 shares at $33.00 per share, representing a $49,999,983.00 investment and his first shareholding in CGON. The company is in a growth-stage oncology phase: annual revenue growth reached +458.3%, yet the company posted a net loss of $41,426,000.00 over its most recent full fiscal year with $0.00 in latest quarterly revenue. The stock currently trades at $34.60, up 34.6% over the past 30 days and 31.9% over 90 days, placing it within the 52-week range of $15.59–$39.94. This large-scale inaugural purchase by a director of a clinical or pre-revenue biotech firm signals engagement with the company's clinical or commercial trajectory during a period of significant recent share appreciation.

Director Song Hong Fang sells 100,000 CGON shares for $2.8M at $27.80 avg; stock now $30.94, up 14.8% in 30d

Director Song Hong Fang executed 4 separate sales totaling 100,000 shares (100.0K shares) for $2,779,542.20 ($2.8M) on September 3, 2025 at a blended average price of $27.80, reducing his position by 3.3% from 3.00M to 2.90M shares. The sale occurred while the stock trades at $30.94 current price, representing a 22.5% discount from the 52-week high of $39.94, though the stock has posted a 30-day return of +14.8% and 90-day return of +15.0% since the transaction date. His prior CGON trade history shows perfect timing at the 90-day mark across 4 prior trades, including a well-timed sell on 2024-12-16 that preceded a 90-day decline of -0.7% and another on 2024-08-29 that preceded a 90-day decline of -3.6%. The company remains unprofitable with a net income of $-41,426,000.00 ($-41.4M) despite explosive 458.3% annual revenue growth, adding context to insider sales in an early-stage growth company.

Director Song Hong Fang sold 700,000 shares of CGON at $28.00 for $19.6M on 2024-12-16.

Song Hong Fang, a Director at CG Oncology, sold 700,000 shares (700.0K shares) at $28.00 on 2024-12-16, reducing holdings by 18.9% to 3,003,931 shares. The stock has since declined 11.0% over 30 days and 21.0% over 90 days from the sale date, currently trading at $29.27—38.9% below its 52-week high of $47.93. The sale timing aligns with Fang's prior pattern: across 3 prior trades at CGON, his 2 prior sells both posted negative 90-day returns (-3.6%), and his cross-ticker track record shows a 100.00% well-timed sell rate (higher is better for sells). The company's fundamentals remain challenged: latest quarterly revenue is $43,000 ($43.0K) with a net loss of $-20,405,000 ($-20.4M), despite a $2.0B market cap. The magnitude of this sale—$19.6M—represents a significant reduction in a Director's CGON exposure and occurs during a period of deteriorating stock performance.

Director Song Hong Fang sold 650,455 shares ($23.0M) at $35.36 on 2024-08-29, reducing stake by 14.9%.

Song Hong Fang, a director, executed 2 separate sales totaling 650,455 shares for $23,000,088.80, reducing his holdings from 4,354,386 shares to 3,703,931 shares. The shares sold at $35.36 are now trading at $36.88, representing a $1.52 gap above the transaction price. In his cross-ticker track record, Fang's 1 prior buy averaged +133.7% over 90 days with a 100% win rate, and at CGON specifically his prior buy on 2024-01-29 achieved +133.7% and +115.8% returns over 30 and 90 days respectively. The current sale removes substantial holdings but occurs against positive recent price momentum (+10.6% over 30 days, +13.2% over 90 days). CGON is unprofitable with $-18.9M net income against $111.0K revenue in the latest quarter and a market cap of $2,473,800,497.60, warranting scrutiny of the company's path to profitability.